Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Neoplasm Metastasis × nilotinib × Clear all

Phase

Phase 2 5 Phase 3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17 Leukemia 6 Philadelphia Chromosome 3 Leukemia, Myeloid, Chronic-Phase 3 Gastrointestinal Stromal Tumors 3 Neoplasms 2 Myeloproliferative Disorders 2 Bronchiolitis Obliterans Syndrome 2 Sarcoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms by Histologic Type 1 Neoplasm Metastasis 1 Leukemia, Myeloid 1 Hematologic Diseases 1 Bone Marrow Diseases 1

Interventions

Leucovorin 20 Fluorouracil 20 Capecitabine 19 Docetaxel 18 Gemcitabine 17 Paclitaxel 16 Radiosurgery 13 Irinotecan 13 Carboplatin 12 Zoledronic Acid 11 Oxaliplatin 11 Cisplatin 11 Radiotherapy 10 Fulvestrant 10 Bevacizumab 10 Drug Therapy 9 pembrolizumab 8 Pemetrexed 8 palbociclib 7 Surgical Procedures, Operative 7 Ibandronic Acid 7 Prednisone 6 130-nm albumin-bound paclitaxel 6 abemaciclib 5 Vinorelbine 5 Letrozole 5 Folfox protocol 5 Floxuridine 5 Doxorubicin 5 Cetuximab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03784014 2025-12-11

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Active not recruiting

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡